The Alaska legislature recently passed Senate Bill 196 (SB 196), giving employers who choose to comply with the state’s voluntary drug testing law the option to use oral fluid in their workplace(s).
In recent years, the increasing legalization and widespread use of cannabis products have led to a surge in confusion among employers and employees regarding the differences between THC, synthetic THC, and CBD. With various products in the market and shifting legal landscapes, understanding these substances is critical, especially regarding workplace policies and drug testing.
The landscape of cannabis regulation in the United States is on the verge of a significant transformation. In May 2024, the Attorney General published a Notice of Proposed Rulemaking (NPRM) that could see marijuana reclassified from a Schedule I to a Schedule III substance under the Controlled Substances Act (CSA). This proposed change follows directives from President Biden and recommendations from the Department of Health and Human Services (HHS). In a recent webinar, Faye Caldwell, Attorney at Law at Caldwell Everson PLLC, discussed the changes. Here's what you need to know.
The rise of fentanyl abuse poses significant challenges to workplace safety and productivity. Addressing these challenges requires comprehensive understanding and proactive measures. In a recent webinar, Lance Presley, an expert from Labcorp, discussed the impact of fentanyl on the workplace and the critical steps employers should take to mitigate its risks. Here's what you need to know.
New guidance from the Office of Drug and Alcohol Policy and Compliance (ODAPC) on behalf of each DOT Agency has been issued, impacting the process for converting federally regulated drug tests to non-regulated status. Below, we detail these updated procedures and their implications for our clients and Medical Review Officers (MROs).
Minnesota recently adjusted its mandatory drug, alcohol, and cannabis testing law to permit employers to perform oral fluid testing that is exempt from the state’s laboratory testing requirements. Though the updates do not specifically use the words “rapid result” or “onsite”, it clearly states that oral fluid can be used for non-laboratory testing and results must be given at the time a test occurs, making it clear that it is referring to POCT oral fluid. Oral fluid tests complying with the regulatory updates will be permitted as of August 1, 2024, for drug, alcohol, and cannabis testing purposes.
DISA Global Solutions was recently featured in an article from NETA World’s Spring 2024 Journal, the quarterly journal published by the InterNational Electrical Testing Association (NETA). We have republished it below with permission from NETA World. Visit www.netaworld.org for more information.
In an era where the normalization of marijuana contrasts starkly with the escalating crisis of fentanyl abuse, employers face an unprecedented challenge in maintaining safe and compliant workplaces. It’s essential HR professionals understand the evolving dynamics of workplace drug testing, between the legalization of marijuana and the alarming rise of fentanyl.
